Ensign Peak Advisors
SRNE

Ensign Peak Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Ensign Peak Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-88,990
Closed -$414K – 2264
2021
Q4 		$414K Buy
+88,990
New +$552K ﹤0.01% 1692

Other funds holding SRNE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Ensign Peak Advisors's SRNE Position: Q1 2022 in Review

Ensign Peak Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2022, closing a stake of 88,990 shares — an estimated $414K sold.

Ensign Peak Advisors first reported a position in SRNE in Q4 2021 and held it in 1 quarter. The position peaked at $414K in Q4 2021. 235 funds tracked by Wall St. Rank hold SRNE as of Q1 2022.

  • Ensign Peak Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 88,990 Sorrento Therapeutics, Inc. shares in Q1 2022, an estimated $414K.
  • Ensign Peak Advisors first reported a position in Sorrento Therapeutics, Inc. in Q4 2021 and held it in 1 quarter.
  • Ensign Peak Advisors's Sorrento Therapeutics, Inc. position peaked at $414K in Q4 2021.
  • 235 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2022.

Based on Ensign Peak Advisors's 13F filing for Q1 2022, filed 16 May 2022.